Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    ...
    154
    ...
ATC Name B/G Ingredients Dosage Form Price
N05AH04 QUETIAPINE/ GENEPHARM G Quetiapine - 100mg 100mg Tablet, film coated 1,569,608 L.L
N05AH04 SEROPINE 100 G Quetiapine fumarate - 100mg 100mg Tablet, film coated 1,996,950 L.L
N05AH04 JOSWE QUZAL 200 G Quetiapine - 200mg 200mg Tablet 1,130,172 L.L
N05AH04 JOSWE QUZAL 200 G Quetiapine - 200mg 200mg Tablet 2,147,460 L.L
N05AH04 QUETIAPINE/ GENEPHARM G Quetiapine - 200mg 200mg Tablet, film coated 2,991,393 L.L
N05AH04 QUETIAKEY G Quetiapine fumarate - 300mg 300mg Tablet, film coated 1,947,228 L.L
N05AH04 QUETIAPINE/ GENEPHARM G Quetiapine - 300mg 300mg Tablet, film coated 1,988,887 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 200mg 200mg Tablet, extended release 2,116,552 L.L
N05AH04 QUETIAPINE BIOGARAN L.P. G Quetiapine fumarate - 300mg 300mg Tablet, prolonged release 1,759,090 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 300mg 300mg Tablet, extended release 2,535,831 L.L
N05AH04 SEROPINE XR 300 G Quetiapine fumarate - 300mg 300mg Tablet, extended release 4,744,660 L.L
N05AH04 QUETIAPINE BIOGARAN L.P. G Quetiapine fumarate - 50mg 50mg Tablet, prolonged release 1,010,570 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 50mg 50mg Tablet, extended release 533,505 L.L
N05AH04 JOSWE QUZAL 400 G Quetiapine - 400mg 400mg Tablet 2,697,092 L.L
N05AH04 JOSWE QUZAL 400 G Quetiapine - 400mg 400mg Tablet 5,124,071 L.L
N05AH04 QUETIAPINE BIOGARAN L.P. G Quetiapine fumarate - 400mg 400mg Tablet, prolonged release 2,612,430 L.L
N05AL05 SOLIAN B Amisulpride - 100mg 100mg Tablet, scored 1,048,197 L.L
N05AL05 SOLIAN B Amisulpride - 400mg 400mg Tablet, film-scored 1,764,465 L.L
N05AL07 DISLEP G Levosulpiride - 25mg 25mg Tablet 1,690,682 L.L
N05AN01 MANICARB SR-400 G Lithium carbonate - 400mg 400mg Tablet, prolonged release 1,431,192 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet, film coated 306,396 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet, film coated 306,396 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg 1mg Tablet 823,775 L.L
N05AX08 RESPAL 1 G Risperidone - 1mg 1mg Caplet, film coated 309,084 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 1mg 1mg Tablet, coated, scored 643,701 L.L
N05AX08 RISPERDAL B Risperidone - 1mg/ml 1mg/ml Solution 1,377,439 L.L
N05AX08 RISPERDAL B Risperidone - 1mg/ml 1mg/ml Solution 1,377,439 L.L
N05AX08 DEPIA ORAL SOLUTION G Risperidone - 1mg/ml 1mg/ml Solution 1,510,223 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg/ml 1mg/ml Solution 604,729 L.L
N05AX08 RISPERDAL B Risperidone - 2mg 2mg Tablet, film coated 306,396 L.L
    ...
    154
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025